세계 근이완제 시장 조사 보고서 : 산업 분석, 규모, 점유율, 성장, 동향 예측(2024-2032년)

The global demand for Muscle Relaxant Drugs Market is presumed to reach the market size of nearly USD 6.69 Billion by 2032 from USD 4.23 Billion in 2023 with a CAGR of 5.22% under the study period 2024-2038.

Muscle Relaxant Drugs are a special class of drugs used in the treatment of several discomforts caused to the muscle like spasms, pain, and cramps due to dehydration or fatigue. These drugs do not act on the central nervous system but work on the neurons used for signal transmission between the brain and the spinal cord. They are used during surgical procedures as well to relax the muscles. Few of the muscle relaxant drugs currently in the market approved by the FDA are baclofen, metaxalone, and orphenadrine. Generally, muscle relaxants are very powerful drugs which are addictive and can have side effects. Drugs used for removing wrinkles on the face like Botox can also be fit under this class of drugs since their use is like that of a relaxant.

MARKET DYNAMICS

The growing geriatric population and changing lifestyles are the main drivers of the muscle relaxant drugs market. The rise in the number of surgical procedures carried out globally and the use of these drugs along with anaesthetic to relax a patient's muscle can further propel the growth of this market. Increased rate of pollution and exposure to UV rays can cause certain skin conditions which can be treated using these drugs. The market for muscle relaxant drugs will show a great deal of growth during COVID-19 lockdown since many people can suffer from muscular discomforts due to lack of physical activity. Stringent rules imposed by governments, risks involved, and high costs associated with the drugs can obscure the growth of the muscle relaxant drugs market.

The research report covers Porter's Five Forces Model, Market Attractiveness Analysis, and Value Chain analysis. These tools help to get a clear picture of the industry's structure and evaluate the competition attractiveness at a global level. Additionally, these tools also give an inclusive assessment of each segment in the global market of Muscle Relaxant Drugs. The growth and trends of Muscle Relaxant Drugs industry provide a holistic approach to this study.

MARKET SEGMENTATION

This section of the Muscle Relaxant Drugs market report provides detailed data on the segments at country and regional level, thereby assisting the strategist in identifying the target demographics for the respective product or services with the upcoming opportunities.

By Drug Type

• Skeletal Muscle Relaxant Drugs
• Facial Muscle Relaxant Drugs
• Neuromuscular Blocking Agents

By Route of Administration

• Oral
• Injectable

By Distribution Channel

• Hospital Pharmacy
• Retail Pharmacy
• Online Pharmacy

REGIONAL ANALYSIS

This section covers the regional outlook, which accentuates current and future demand for the Muscle Relaxant Drugs market across North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. Further, the report focuses on demand, estimation, and forecast for individual application segments across all the prominent regions.

The research report also covers the comprehensive profiles of the key players in the market and an in-depth view of the competitive landscape worldwide. The major players in the Muscle Relaxant Drugs market include Amneal Pharmaceuticals LLC, Ipsen Biopharmaceuticals Inc., Merz Pharmaceuticals LLC., Par Pharmaceutical, Endo Pharmaceuticals, Vertical Pharmaceuticals, Mallinckrodt, SteriMax, Eisai Co. Ltd, Metacel Pharmaceuticals LLC., Teva Pharmaceuticals USA Inc. This section consists of a holistic view of the competitive landscape that includes various strategic developments such as key mergers & acquisitions, future capacities, partnerships, financial overviews, collaborations, new product developments, new product launches, and other developments.

In case you have any custom requirements, do write to us. Our research team can offer a customized report as per your need.

TABLE OF CONTENTS

1. PREFACE

• 1.1. Report Description
  • 1.1.1 Objective
  • 1.1.2 Target Audience
  • 1.1.3 Unique Selling Proposition (USP) & offerings
• 1.2. Research Scope
• 1.3. Research Methodology
  • 1.3.1 Market Research Process
  • 1.3.2 Market Research Methodology

2. EXECUTIVE SUMMARY

• 2.1. Highlights of Market
• 2.2. Global Market Snapshot

3. MUSCLE RELAXANT DRUGS - INDUSTRY ANALYSIS

• 3.1. Introduction - Market Dynamics
• 3.2. Market Drivers
• 3.3. Market Restraints
• 3.4. Opportunities
• 3.5. Industry Trends
• 3.6. Porter's Five Force Analysis
• 3.7. Market Attractiveness Analysis
  • 3.7.1 Market Attractiveness Analysis By Drug Type
  • 3.7.2 Market Attractiveness Analysis By Route of Administration
  • 3.7.3 Market Attractiveness Analysis By Distribution Channel
  • 3.7.4 Market Attractiveness Analysis By Region

4. VALUE CHAIN ANALYSIS

• 4.1. Value Chain Analysis
• 4.2. Raw Material Analysis
  • 4.2.1 List of Raw Materials
  • 4.2.2 Raw Material Manufactures List
  • 4.2.3 Price Trend of Key Raw Materials
• 4.3. List of Potential Buyers
• 4.4. Marketing Channel
  • 4.4.1 Direct Marketing
  • 4.4.2 Indirect Marketing
  • 4.4.3 Marketing Channel Development Trend

5. GLOBAL MUSCLE RELAXANT DRUGS MARKET ANALYSIS BY DRUG TYPE

• 5.1. Overview By Drug Type
• 5.2. Historical and Forecast Data
• 5.3. Analysis By Drug Type
• 5.4. Skeletal Muscle Relaxant Drugs Historic and Forecast Sales By Regions
• 5.5. Facial Muscle Relaxant Drugs Historic and Forecast Sales By Regions
• 5.6. Neuromuscular Blocking Agents Historic and Forecast Sales By Regions

6. GLOBAL MUSCLE RELAXANT DRUGS MARKET ANALYSIS BY ROUTE OF ADMINISTRATION

• 6.1. Overview By Route of Administration
• 6.2. Historical and Forecast Data
• 6.3. Analysis By Route of Administration
• 6.4. Oral Historic and Forecast Sales By Regions
• 6.5. Injectable Historic and Forecast Sales By Regions

7. GLOBAL MUSCLE RELAXANT DRUGS MARKET ANALYSIS BY DISTRIBUTION CHANNEL

• 7.1. Overview By Distribution Channel
• 7.2. Historical and Forecast Data
• 7.3. Analysis By Distribution Channel
• 7.4. Hospital Pharmacy Historic and Forecast Sales By Regions
• 7.5. Retail Pharmacy Historic and Forecast Sales By Regions
• 7.6. Online Pharmacy Historic and Forecast Sales By Regions

8. GLOBAL MUSCLE RELAXANT DRUGS MARKET ANALYSIS BY GEOGRAPHY

• 8.1. Regional Outlook
• 8.2. Introduction
• 8.3. North America Sales Analysis
  • 8.3.1 Overview, Historic and Forecast Data Sales Analysis
  • 8.3.2 North America By Segment Sales Analysis
  • 8.3.3 North America By Country Sales Analysis
  • 8.3.4 United States Sales Analysis
  • 8.3.5 Canada Sales Analysis
  • 8.3.6 Mexico Sales Analysis
• 8.4. Europe Sales Analysis
  • 8.4.1 Overview, Historic and Forecast Data Sales Analysis
  • 8.4.2 Europe By Segment Sales Analysis
  • 8.4.3 Europe By Country Sales Analysis
  • 8.4.4 United Kingdom Sales Analysis
  • 8.4.5 France Sales Analysis
  • 8.4.6 Germany Sales Analysis
  • 8.4.7 Italy Sales Analysis
  • 8.4.8 Russia Sales Analysis
  • 8.4.9 Rest Of Europe Sales Analysis
• 8.5. Asia Pacific Sales Analysis
  • 8.5.1 Overview, Historic and Forecast Data Sales Analysis
  • 8.5.2 Asia Pacific By Segment Sales Analysis
  • 8.5.3 Asia Pacific By Country Sales Analysis
  • 8.5.4 China Sales Analysis
  • 8.5.5 India Sales Analysis
  • 8.5.6 Japan Sales Analysis
  • 8.5.7 South Korea Sales Analysis
  • 8.5.8 Australia Sales Analysis
  • 8.5.9 South East Asia Sales Analysis
  • 8.5.10 Rest Of Asia Pacific Sales Analysis
• 8.6. Latin America Sales Analysis
  • 8.6.1 Overview, Historic and Forecast Data Sales Analysis
  • 8.6.2 Latin America By Segment Sales Analysis
  • 8.6.3 Latin America By Country Sales Analysis
  • 8.6.4 Brazil Sales Analysis
  • 8.6.5 Argentina Sales Analysis
  • 8.6.6 Peru Sales Analysis
  • 8.6.7 Chile Sales Analysis
  • 8.6.8 Rest of Latin America Sales Analysis
• 8.7. Middle East & Africa Sales Analysis
  • 8.7.1 Overview, Historic and Forecast Data Sales Analysis
  • 8.7.2 Middle East & Africa By Segment Sales Analysis
  • 8.7.3 Middle East & Africa By Country Sales Analysis
  • 8.7.4 Saudi Arabia Sales Analysis
  • 8.7.5 UAE Sales Analysis
  • 8.7.6 Israel Sales Analysis
  • 8.7.7 South Africa Sales Analysis
  • 8.7.8 Rest Of Middle East And Africa Sales Analysis

9. COMPETITIVE LANDSCAPE OF THE MUSCLE RELAXANT DRUGS COMPANIES

• 9.1. Muscle Relaxant Drugs Market Competition
• 9.2. Partnership/Collaboration/Agreement
• 9.3. Merger And Acquisitions
• 9.4. New Product Launch
• 9.5. Other Developments

10. COMPANY PROFILES OF MUSCLE RELAXANT DRUGS INDUSTRY

• 10.1. Top Companies Market Share Analysis
• 10.2. Market Concentration Rate
• 10.3. Amneal Pharmaceuticals LLC
  • 10.3.1 Company Overview
  • 10.3.2 Company Revenue
  • 10.3.3 Products
  • 10.3.4 Recent Developments
• 10.4. Ipsen Biopharmaceuticals Inc.
  • 10.4.1 Company Overview
  • 10.4.2 Company Revenue
  • 10.4.3 Products
  • 10.4.4 Recent Developments
• 10.5. Merz Pharmaceuticals LLC.
  • 10.5.1 Company Overview
  • 10.5.2 Company Revenue
  • 10.5.3 Products
  • 10.5.4 Recent Developments
• 10.6. Par Pharmaceutical
  • 10.6.1 Company Overview
  • 10.6.2 Company Revenue
  • 10.6.3 Products
  • 10.6.4 Recent Developments
• 10.7. Endo Pharmaceuticals
  • 10.7.1 Company Overview
  • 10.7.2 Company Revenue
  • 10.7.3 Products
  • 10.7.4 Recent Developments
• 10.8. Vertical Pharmaceuticals
  • 10.8.1 Company Overview
  • 10.8.2 Company Revenue
  • 10.8.3 Products
  • 10.8.4 Recent Developments
• 10.9. Mallinckrodt
  • 10.9.1 Company Overview
  • 10.9.2 Company Revenue
  • 10.9.3 Products
  • 10.9.4 Recent Developments
• 10.10. SteriMax
  • 10.10.1 Company Overview
  • 10.10.2 Company Revenue
  • 10.10.3 Products
  • 10.10.4 Recent Developments
• 10.11. Eisai Co. Ltd
  • 10.11.1 Company Overview
  • 10.11.2 Company Revenue
  • 10.11.3 Products
  • 10.11.4 Recent Developments
• 10.12. Metacel Pharmaceuticals LLC.
  • 10.12.1 Company Overview
  • 10.12.2 Company Revenue
  • 10.12.3 Products
  • 10.12.4 Recent Developments
• 10.13. Teva Pharmaceuticals USA Inc
  • 10.13.1 Company Overview
  • 10.13.2 Company Revenue
  • 10.13.3 Products
  • 10.13.4 Recent Developments

Note - In company profiling, financial details and recent developments are subject to availability or might not be covered in the case of private companies